Journal article
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Abstract
BACKGROUND: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.
METHODS: This multicentre, …
Authors
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D
Journal
The Lancet Oncology, Vol. 25, No. 4, pp. 463–473
Publisher
Elsevier
Publication Date
April 2024
DOI
10.1016/s1470-2045(24)00070-6
ISSN
1470-2045